FIELD: medicine.
SUBSTANCE: invention refers to application of p21-activated kinase (PAK1) inhibitor for arthropathy treatment, including osteoarthritis or rheumatoid arthritis, or for joint pain management, and to application of PAK1 as a target protein for searching PAK1 inhibitor as a drug for arthropathy treatment.
EFFECT: reduced or eliminated impact of cartilage-damaging factors.
21 cl, 6 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| RA ANTIGEN PEPTIDES | 2004 |
|
RU2359974C2 |
| IL-1beta-BINDING ANTIBODIES AND FRAGMENTS THEREOF | 2006 |
|
RU2518295C2 |
| RECOVERED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT (VERSIONS), METHOD OF TREATING hTNFα-MEDIATED DISEASES WITH MEDIATION THEREOF (VERSIONS), PHARMACEUTICAL COMPOSITION, RECOMBINANT HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, RECOVERED NUCLEIC ACID (VERSIONS) | 2005 |
|
RU2458704C9 |
| HETERODIMERIC POLIPEPTIDES IL-17 A/F AND POSSIBILITIES OF THEIR THERAPEUTIC APPLICATION | 2007 |
|
RU2440134C2 |
| APPLICATION OF SERUM AMYLOID A GENE FOR DIAGNOSIS AND THERAPY OF GLAUCOMA AND IDENTIFICATION OF ANTIGLAUCOMATOUS AGENT | 2007 |
|
RU2461378C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
| ISOLATED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, ISOLATED NUCLEIC ACID (VARIANTS), RECOMBINANT EXPRESSION VECTOR, USING HOST-CELLS FOR EXPRESSION OF ANTIBODY AND METHOD FOR ITS SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITION OF ACTIVITY OF HUMAN TNFα | 1997 |
|
RU2268266C2 |
| ANTI-IL-1R1 BINDING MEMBERS | 2009 |
|
RU2555532C2 |
| METHOD OF TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS | 2006 |
|
RU2419450C2 |
| GENETIC CASSETTE CONTAINING CODON-OPTIMIZED NUCLEOTIDE SEQUENCES OF TRAIL, PTEN AND IFNβ-1 GENES, AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ONCOLOGIC DISEASES | 2020 |
|
RU2757502C1 |
